A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Paliperidone (Primary) ; Antipsychotics
- Indications Psychotic disorders; Schizophrenia
- Focus Therapeutic Use
- Acronyms DREaM
- Sponsors Janssen
- 15 Dec 2017 Planned End Date changed from 19 Nov 2019 to 31 Jan 2020.
- 24 May 2017 Results presented at the 170th Annual Meeting of the American Psychiatric Association
- 24 May 2017 Baseline demographics and clinical characteristics (n=71, as of Sep 2016, US population), presented at the 170th Annual Meeting of the American Psychiatric Association.